Ridinilazole
SMT19969/C004
Phase 3 small_molecule completed
Quick answer
Ridinilazole for Clostridioides Difficile Infection is a Phase 3 program (small_molecule) at Summit Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Summit Therapeutics
- Indication
- Clostridioides Difficile Infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed